Oxervate (Cenegermin-Bkbj) Patent Expiration, LOE Window & CMS Spending

Oxervate (Cenegermin-Bkbj) by Dompe Farmaceutici: Biologic BLA (Purple Book Regime), 0 AB generics, $781.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDompe Farmaceutici
FDA Application & PathwayB761094 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$781.6M
2024 Medicare Part D Spend$714.5M
2024 Medicaid Spend$67.1M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 19.0% 2-yr change)